As of March 1, 2018, new precertification requirements are in effect
AmeriHealth Pennsylvania members for the following specialty drugs that are
eligible for coverage under the medical benefit:
- Durolane® (hyaluronic acid)
- IxifiTM (infliximab-qbtx)
- Lutathera (lutetium [177Lu] oxodotreotide)
- OgivriTM (trastuzumab-dkst)
- PemfexyTM (pemetrexed)
- TriViscTM (sodium hyaluronate)
These changes are reflected in an updated precertification requirement list,
which has been posted to our
website.